Get latest information about COVID-19 vaccine

Current Projects


Project HOUDINI LINK (Hospital Opioid Use Disorder treatment INItiation and LINKage to care) is a SAMHSA funded project that studies the efficacy of a novel 6-month care coodination program, consisting of lay patient navigators, contingency management and motivational interviewing, on (1) linkage rates to community-based treatment (2) ongoing treatment engagement and (3) health care utilization for patients initiating medications for OUD while hopsitalized at Zuckerberg San Francisco General Hopsital.


Z-1701 is an outpatient randomized within subject placebo-controlled human laboratory investigation of analgesia (as assessed with quantitative sensory testing; QST) from ketamine alone and in combination with hydromorphone in buprenorphine-maintained participants. The goals of this project are to characterize the analgesic, subjective, and physiologic effects of ketamine combined with hydromorphone in patients on buprenorphine maintenance for opioid use disorder.


CTN-0080 (Medication Treatment for Opioid Use Disorder in Expectant Mothers (MOMs)) is a multi-site randomized controlled non-inferiority clinical trial that evaluates the impact of treating OUD in pregnant women with extended-release buprenorphine (BUP-XR), compared to sublingual buprenorphine (BUP-SL), on mother and infant outcomes.


Z-1901 is a controlled human laboratory study examining how two stressors, chronic pain and mild opioid withdrawal, affect decision making in patients on methadone maintenance. This study will test how chronic pain is associated with increases in impulsive decision making in OUD, whether impulsive decision making is greater when undergoing opioid withdrawal, and how pain catastrophizing may modify the association between withdrawal and impulsive decision making in patients with chronic pain and OUD.


Z-2001 examines the acceptability and feasibility of an FDA-cleared prescription digital therapeutic, reSET®/reSET-O® in patients with OUD enrolled at OTOP/Ward 93 during the COVID-19 pandemic. reSET® and reSET® are smartphone applications that combine interactive cognitive behavioral therapy modules, in-app reminders to track use and triggers, as well as financial incentives for module completion and in-clinic urine drug screen results.
Lastly, we conducted qualitative and quantitative data on the myriad of regulatory and practice changes that occurred in the delivery of care to patients with OUD because of the COVID-19 pandemic. For example, we demonstrated that distributing flip phones could improve adherence with telephone counseling and may improve retention in treatment in patients enrolled in a licensed opioid treatment program (OTOP/Ward 93).


  • If you are interested in joining a study, please call us at (628) 206-3365
  • If you are interested in a career in research at DSAAM, please see our current job openings
  • If you are interested in a post-doctoral fellowship, research opportunity as part of a degree program or volunteer
    opportunity please email Dr.Tompkins 

Recent Publications

Methadone maintenance patients lack analgesic response to a cumulative intravenous dose of 32 mg of hydromorphone.

Agin-Liebes G, Huhn AS, Strain EC, Bigelow GE, Smith MT, Edwards RR, Gruber VA, Tompkins DA. Drug Alcohol Depend. 2021

Recovery Goals and Long-term Treatment Preference in Persons Who Engage in Nonmedical Opioid Use.

Hay KR, Huhn AS, Tompkins DA, Dunn KE. J Addict Med. 2019

Efficacy of Tramadol Extended-Release for Opioid Withdrawal: A Randomized Clinical Trial.

Dunn KE, Tompkins DA, Bigelow GE, Strain EC. JAMA Psychiatry. 2017

“I wanted something that was more flexible”: a qualitative study of patient preferences on choosing buprenorphine over methadone in a safety-net hospital opiate treatment program.

Checkley L, Steiger S, Knight KR.Subst Abus. in press

Homelessness, housing instability, and abortion outcomes at an urban abortion clinic in the United States

Orlando MS, Vable AM, Holt K, Wingo E, Newmann S, Shapiro BJ, Borne D, Drey EA, Seidman D.Am J Obstet Gynecol. 2020